SCYX - SCYNEXIS, Inc. News

Discover

SCYX

SCYNEXIS, Inc.

5.24

26 x 5.23

2 x 5.52

bid

ask

0.04

0.77%

12 @ 04:00 PM

5.25 +0.01 (0.26%)

Ytd	3.56%
1y	-25.14%

5.21

day range

5.52

3.57

52 week range

9.44

Open	5.25	Prev Close	5.20	Low	5.21	High	5.52	Mkt Cap	32.95M
Vol	94.60K	Avg Vol	132.53K	EPS	-3.42	P/E	-1.53	Forward P/E	6.80
Beta	1.50	Short Ratio	5.04	Inst. Own	44.31%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	05-11	50-d Avg	4.44	200-d Avg	5.73	1yr Est	6.67

SCYX News

defenseworld.net

SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200 Day Moving Average – Time to Sell?

SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed below its two hundred day moving avera

globenewswire.com

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal D

JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage

globenewswire.com

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Com

globenewswire.com

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage

globenewswire.com

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N. J. , May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) ("SCYNEXIS" or t

seekingalpha.com

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Th

businesswire.com

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinica

globenewswire.com

SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or

globenewswire.com

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AM

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the u

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

globenewswire.com

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

globenewswire.com

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascendin

JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

globenewswire.com

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC

defenseworld.net

Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Repo

globenewswire.com

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

globenewswire.com

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

globenewswire.com

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

defenseworld.net

SCYNEXIS (SCYX) to Release Earnings on Wednesday

SCYNEXIS (NASDAQ: SCYX - Get Free Report) is anticipated to announce its Q3 2025 results before the

globenewswire.com

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

globenewswire.com

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-

JERSEY CITY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

benzinga.com

Stocks That Hit 52-Week Lows On Monday